L.L. Siu

1.6k total citations · 1 hit paper
30 papers, 1.1k citations indexed

About

L.L. Siu is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, L.L. Siu has authored 30 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 9 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in L.L. Siu's work include Cancer Immunotherapy and Biomarkers (7 papers), CAR-T cell therapy research (4 papers) and Lung Cancer Research Studies (4 papers). L.L. Siu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), CAR-T cell therapy research (4 papers) and Lung Cancer Research Studies (4 papers). L.L. Siu collaborates with scholars based in Canada, United States and Taiwan. L.L. Siu's co-authors include Aaron R. Hansen, Daphne Day, Tom Wei‐Wu Chen, Leila Khoja, Sébastien J. Hotte, Susan Turner, L. Wang, Nicole G. Chau, Malcolm J. Moore and Dipanwita Banerjee and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

L.L. Siu

28 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review

2017 678 citations Leila Khoja, Daphne Day et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
L.L. Siu Canada	10	833	290	248	247	179	30	1.1k
Sandra J. Casak United States	18	455 0.5×	215 0.7×	171 0.7×	189 0.8×	138 0.8×	32	1.0k
Keita Kudo Japan	13	1.0k 1.2×	611 2.1×	173 0.7×	122 0.5×	193 1.1×	35	1.3k
Dylan J. Martini United States	17	729 0.9×	422 1.5×	166 0.7×	186 0.8×	152 0.8×	68	1.0k
Mona Fouad Egypt	16	638 0.8×	278 1.0×	157 0.6×	95 0.4×	93 0.5×	32	896
Hiroki Ueda Japan	16	653 0.8×	307 1.1×	116 0.5×	112 0.5×	108 0.6×	58	916
Wenzhuo He China	19	878 1.1×	279 1.0×	241 1.0×	296 1.2×	250 1.4×	84	1.3k
Seong Hyun Jeong South Korea	17	362 0.4×	204 0.7×	216 0.9×	147 0.6×	104 0.6×	67	761
Shaad E. Abdullah United States	16	573 0.7×	271 0.9×	168 0.7×	139 0.6×	211 1.2×	63	911
Natsuko Okita Japan	20	855 1.0×	518 1.8×	278 1.1×	271 1.1×	105 0.6×	110	1.3k
Ryoji Kato Japan	13	1.2k 1.4×	711 2.5×	206 0.8×	121 0.5×	198 1.1×	24	1.4k

Countries citing papers authored by L.L. Siu

Since Specialization

Citations

This map shows the geographic impact of L.L. Siu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L.L. Siu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L.L. Siu more than expected).

Fields of papers citing papers by L.L. Siu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L.L. Siu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L.L. Siu. The network helps show where L.L. Siu may publish in the future.

Co-authorship network of co-authors of L.L. Siu

This figure shows the co-authorship network connecting the top 25 collaborators of L.L. Siu. A scholar is included among the top collaborators of L.L. Siu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L.L. Siu. L.L. Siu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Siu, L.L., et al.. (2022). 750P Phase I study of TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa (BA) in patients (pts) with metastatic/locally advanced solid unresectable tumours. Annals of Oncology. 33. S887–S887. 4 indexed citations

Rose, April A. N., Sofia Genta, Deirdre Kelly, et al.. (2021). 531P Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Preliminary results of the investigator initiated phase II BEAVER trial. Annals of Oncology. 32. S596–S596.

Hamid, Omid, et al.. (2021). 488 Phase 1 trial of first-in-class anti-CD96 monoclonal antibody inhibitor, GSK6097608, monotherapy and combination with anti–PD-1 monoclonal antibody, dostarlimab, in advanced solid tumors. SHILAP Revista de lepidopterología. A518–A518. 4 indexed citations

Harrington, Kevin J., Ezra E.W. Cohen, L.L. Siu, et al.. (2020). 351 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009. SHILAP Revista de lepidopterología. A214.1–A214. 2 indexed citations

Yap, Timothy A., Daniel Vilarim Araújo, Debra L. Wood, et al.. (2020). P856 AVID200, first-in-class TGF-beta1 and beta3 selective inhibitor: results of a phase 1 monotherapy dose escalation study in solid tumors and evidence of target engagement in patients. Poster presentations. A6.2–A7. 8 indexed citations

Mesı́a, Ricard, Paolo Bossi, Aaron R. Hansen, et al.. (2019). Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma. European Journal of Cancer. 123. 138–145. 14 indexed citations

Ma, Brigette, Frankie Mo, Herbert H. Loong, et al.. (2018). Phase I investigator’s perceptions to ‘supersized seamless trials in oncology'. Annals of Oncology. 29. ix26–ix26.

Spreafico, Anna, Khalil Sultanem, Scott V. Bratman, et al.. (2018). A randomized phase II study of cisplatin plus radiotherapy versus durvalumab plus radiotherapy followed by adjuvant durvalumab versus durvalumab plus radiotherapy followed by adjuvant tremelimumab and durvalumab in intermediate risk, HPV-positive, locoregionally advanced oropharyngeal squamous cell cancer (LA-OSCC) (Canadian Cancer Trials Group HN.9). Annals of Oncology. 29. viii399–viii399. 7 indexed citations

Khoja, Leila, Daphne Day, Tom Wei‐Wu Chen, L.L. Siu, & Aaron R. Hansen. (2017). Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Annals of Oncology. 28(10). 2377–2385. 678 indexed citations breakdown →

10.

Prawira, Amy, Paul Dufort, Aaron R. Hansen, et al.. (2016). Development of a predictive radiomics signature for response to immune checkpoint inhibitors (ICIs) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN). Annals of Oncology. 27. vi330–vi330. 5 indexed citations

11.

Gilbert, Jill, Christophe Le Tourneau, Hisham Mehanna, et al.. (2015). Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab + tremelimumab, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CONDOR. Journal for ImmunoTherapy of Cancer. 3(S2). 9 indexed citations

12.

Lassen, Ulrik, Didier Meulendijks, L.L. Siu, et al.. (2014). A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers. Clinical Cancer Research. 21(2). 258–266. 32 indexed citations

13.

Lassen, Ulrik, Jan H.M. Schellens, L.L. Siu, et al.. (2012). 29 A First-in-Human Phase I Monotherapy Study of RG7212 (R), a Novel Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Solid Tumors. European Journal of Cancer. 48. 12–12. 4 indexed citations

14.

Chau, Nicole G., et al.. (2011). A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Annals of Oncology. 23(6). 1562–1570. 112 indexed citations

15.

Infante, J. R., L.L. Siu, Dan M. Sullivan, et al.. (2011). 1210 POSTER Phase 1 Study of MLN9708, an Investigational Proteasome Inhibitor, in Advanced Nonhematologic Malignancies- Updated Results. European Journal of Cancer. 47. S147–S147. 2 indexed citations

16.

Tung, Stewart Y., Daniel T. T. Chua, Roger K.C. Ngan, et al.. (2009). 8503 Final report of NPC-9901trial on therapeutic gain and late toxicities attributed to concurrent-adjuvant chemotherapy for T1–4N2–3M0 nasopharyngeal carcinoma. European Journal of Cancer Supplements. 7(2). 471–471. 1 indexed citations

17.

Winquist, Eric, Elizabeth B. Lamont, Sébastien J. Hotte, et al.. (2003). 142 Phase II study of imatinib mesylate in salivary gland adenoid cystic carcinoma. European Journal of Cancer Supplements. 1(5). S46–S47. 7 indexed citations

18.

Siu, L.L., Dipanwita Banerjee, Rohini Khurana, et al.. (1998). The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma.. PubMed. 4(3). 559–65. 55 indexed citations

19.

Siu, L.L., W. Chapman, & Malcolm J. Moore. (1997). Use of the Somatostatin Analogue Octreotide Acetate in the Treatment of Encephalopathy Associated with Carcinoid Tumor. American Journal of Clinical Oncology. 20(6). 558–561. 5 indexed citations

20.

Siu, L.L., Frances A. Shepherd, Nevin Murray, et al.. (1996). Influence of age in the treatment of limited-stage small-cell lung cancer. Pneumologie. 50(7). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact